Results 61 to 70 of about 36,003 (284)
Epileptic Disorders, EarlyView.Abstract Objective Patients with drug‐resistant epilepsy (DRE) typically take multiple anti‐seizure medications (ASMs) and are at risk of treatment‐related adverse events (AEs). This study assessed the impact of cenobamate monotherapy or dual therapy in patients with drug‐resistant epilepsy.
Álvaro Sánchez‐Guijo Benavente +13 more
wiley +1 more source
Frontiers in Pediatrics, 2020 Background: Migraine is the most common acute primary headache in children and adolescents. In 2014, topiramate became the first preventive drug for migraine, approved by the Food and Drug Administration (FDA) for adolescents.
Xinwei Wu +6 more
doaj +1 more source
Acute bilateral simultaneous angle closure glaucoma after topiramate administration: a case report [PDF]
, 2008 Introduction A case of severe acute bilateral angle closure glaucoma with complete visual loss after oral topiramate therapy. Case presentation A 34 year-old woman developed bilateral severe visual loss 2 days after doubling the dosage of topiramate. Her
Kakarla V Chalam +14 more
core +1 more source
Epileptic Disorders, EarlyView.Abstract Objectives Antiseizure medications (ASMs) can induce the activity of drug‐metabolizing enzymes and drug transporters, including cytochrome P450 (CYP)2C9 and P‐glycoprotein (P‐gp). Our objective was to comparatively assess the effects of ASMs on exposure to clinical CYP2C9 and P‐gp substrates.
Hagar Cohen +4 more
wiley +1 more source
A study on the therapeutic effects of Topiramate according to the types of migraine [PDF]
Korean Journal of Pediatrics, 2010 Purpose : The purpose of this study was to evaluate whether the therapeutic effects of topiramate differ according to the types of migraine. Methods : We recruited 38 children and adolescents with migraine who had been treated with topiramate. The effect
Jun Hwa Lee, Kyung Lae Cho
doaj +1 more source
Self‐limited neonatal epilepsy with 2q24.3 duplications: Case series and literature review
Epileptic Disorders, EarlyView.Abstract Objective To clarify the phenotypic spectrum associated with duplications involving the 2q24.3 region, which includes a cluster of genes encoding sodium channel subunits (SCN1A, SCN2A, SCN3A, SCN7A, and SCN9A). Methods We reviewed our research database for patients with epilepsy and 2q24.3 duplication and performed thorough phenotyping.
Saba Al Rawahi, Kenneth A. Myers
wiley +1 more source
Journal of Primary Care & Community Health, 2020 Introduction/Objective: Chronic migraine (CM) is associated with impaired health-related quality of life and substantial socioeconomic burden, but many people with CM are underdiagnosed and do not receive appropriate preventive treatment ...
Andrew M. Blumenfeld +5 more
doaj +1 more source
How Can Network-Pharmacology Contribute to Antiepileptic Drug Development? [PDF]
, 2014 Network-pharmacology is a field of pharmacology emerging from the observation that most clinical drugs have multiple targets, contrasting with the previously dominant magic bullet paradigm which proposed the search of exquisitely selective drugs. What is
Di Ianni, Mauricio Emiliano +1 more
core +1 more source
Newer drugs for focal epilepsy in adults [PDF]
, 2012 A 28 year old woman sees her general practitioner after experiencing what sounds like a convulsion without any apparent provoking factor. Over the past month she has also had “blank spells” during which her husband noticed her to be unresponsive.
Brodie, M., Kwan, P.
core +1 more source
Mechanisms of SCN2A loss of function do not predict presence or phenotype of epilepsy
Epilepsia, EarlyView.Abstract Objective SCN2A loss‐of‐function (LoF) variants are associated with epilepsy (onset age ≥ 3 months), intellectual disability (ID), and autism spectrum disorder (ASD). Despite numerous identified variants and the description of phenotypic subgroups, relationships between Nav1.2 channel dysfunction and clinical phenotypes remain unclear.
Marsha Tan +23 more
wiley +1 more source